Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$7.05 USD
+0.02 (0.28%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $7.03 -0.02 (-0.28%) 4:28 PM ET
2-Buy of 5 2
F Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Adverum Biotechnologies, Inc. [ADVM]
Reports for Purchase
Showing records 1 - 9 ( 9 total )
Company: Adverum Biotechnologies, Inc.
Industry: Medical - Biomedical and Genetics
Ixo-vec Phase 2 Progress For Wet AMD - Looking to LUNA in 4Q24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Adverum Biotechnologies, Inc.
Industry: Medical - Biomedical and Genetics
Hold Your Hastar, ASRS?24 Updates in Wet AMD Gene Therapy Should Be Interpreted Positively
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Adverum Biotechnologies, Inc.
Industry: Medical - Biomedical and Genetics
Boots on the Ground at CTS 2024-New Innovations in the Retina
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Adverum Biotechnologies, Inc.
Industry: Medical - Biomedical and Genetics
Top 23 Takeaways From Our Coverage at the H.C. Wainwright Bioconnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Adverum Biotechnologies, Inc.
Industry: Medical - Biomedical and Genetics
Looking to LUNA - Phase 2 Interim 26-Week Analysis Expected In Near Term; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Adverum Biotechnologies, Inc.
Industry: Medical - Biomedical and Genetics
Novel Gene Therapy Prospect in Wet AMD-Phase 2 Interim Data Expected Mid-2024; Initiating With Buy Rating and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Adverum Biotechnologies, Inc.
Industry: Medical - Biomedical and Genetics
Catching The Next Wave of Innovation: Highlights from Vitreoretinal KOL Call
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Adverum Biotechnologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adverum Biotechnologies, Inc.
Industry: Medical - Biomedical and Genetics
Highlights from wAMD Key Opinion Leader Call: Treat and Extend; Once and Done
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
|